Loading the company…
Loading the company…
Families: DBS & VNS, Sleep apnea & airway implants.
All companies · Product and company coverage
In the last ten years FDA made 49 decisions for Livanova (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 2 procedure families, the most in 2017 (9). The latest was on 2026-10-02.
| Family | Decisions on record |
|---|---|
| DBS & VNS | 191 |
| Sleep apnea & airway implants | 3 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2026-10-02 | PMA | P970003-S254 | VNS Therapy® System · Change Design/Components/Specifications/Material |
| 2026-08-12 | PMA | P970003-S249 | VNS Therapy System · Labeling Change - Indications/instructions/shelf life/tradename |
| 2026-06-18 | PMA | P250013-S002 | aura6000 system · Postapproval Study Protocol |
| 2026-04-30 | PMA | P250013-S001 | aura6000 system · Postapproval Study Protocol |
| 2026-03-18 |
In 2025, Livanova reported engagement with 2,886 surgeons and other clinicians in the states MedaRep covers, worth $2.2M in consulting, speaking, meals and travel for its device products, the most in Texas ($342K to 371). Royalties are left out.
| PMA |
| P250013 |
| aura6000 system · Stimulator, hypoglossal nerve, implanted, apnea |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Livanova.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Texas ($342K, 371 engaged), Missouri ($278K, 49 engaged), California ($212K, 320 engaged), Maryland ($209K, 69 engaged), Ohio ($152K, 90 engaged).